Brief: Actinium Announces Completion of Enrollment Of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
04/11/2021 13:24
Nov 4 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES COMPLETION OF ENROLLMENT OF ACTIMAB-A
CLAG-M
COMBINATION TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE
MYELOID LEUKEMIA FIT FOR INDUCTION THERAPY
* ACTINIUM PHARMACEUTICALS INC - UPDATED PHASE 1 DATA TO BE
PRESENTED AT ASH WITH CLINICAL DEVELOPMENT UPDATE EXPECTED
BEFORE YEAR END
* ACTINIUM PHARMACEUTICALS INC - ASH 2020 DATA REPORTED 100%
REMISSION RATE IN DOSE COHORT 3
* ACTINIUM PHARMACEUTICALS INC - ASH 2020 DATA REPORTED 70%
MRD
NEGATIVITY RATE IN PATIENTS ACHIEVING REMISSION ACROSS ALL DOSE
COHORTS
Source text for Eikon: ID:nPn9YsgMla
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities